Alzheimer’s Disease: Modifying Value Frameworks to Evaluate Current and Emerging Interventions

Published Mar 15, 2021

Value & Outcomes Spotlight Supplement Offers Diverse Perspectives From Leading Experts

Value & Outcomes Spotlight Supplement Cover, March 2021Lawrenceville, NJ, USA—March 15, 2021—Value & Outcomes Spotlight, a bimonthly ISPOR news publication for the global health economics and outcomes research (HEOR) community, announced today the publication of a special supplement exploring value assessment of new interventions in Alzheimer’s disease. The supplement, “Valuing Future Alzheimer’s Disease Treatments: The Need for a Holistic Approach,” was sponsored by Biogen and is based on a series of educational webinars produced by Biogen and ISPOR. The supplement to Value & Outcomes Spotlight was published in March 2021.

Value & Outcomes Spotlight is excited to work with Biogen to promote novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease,” said Zeba M. Khan, RPh, PhD, Editor-in-Chief. “This collaborative project directly aligns with our vision to see Value & Outcomes Spotlight develop a wider presence and attract a broader audience of scholars, payers, industry, and other stakeholders,” added Laura T. Pizzi, PharmD, MPH, Editor-in-Chief.

The supplement opens with 2 editorials. The first by Eric Jutkowitz, PhD, Brown University School of Public Health, Providence, RI, USA, and Joseph Gaugler, PhD, School of Public Health, University of Minnesota, Minneapolis, MN, USA, introduces some of the unique challenges of valuing treatments for Alzheimer’s disease. The second by Paola Barbarino, MA, CEO of Alzheimer’s Disease International, London, England, UK, calls to all stakeholders to collaborate and invest in dementia responses as the economic and social costs of inaction are colossal.

The remaining 3 articles in the supplement provide detailed value assessment perspectives from leading experts in Alzheimer’s disease research:

  1. Defining Elements of Value in Alzheimer’s Disease,” by Garrison, et al, the authors propose that funders should evaluate the value of an Alzheimer’s disease and related dementias intervention from a wide perspective and draw on the “value flower” as an evaluation framework.
  2. Value Assessment in Alzheimer’s Disease: A Focus on Equity,” by Basu, et al, applies the lens of health equity, focusing on the brain equity considerations within a value framework and suggesting the use of an equity-efficacy impact plane to evaluate interventions for Alzheimer’s disease and related dementias.
  3. Long-Term Value Demonstration in Alzheimer’s Disease: Evidence Needs,” by Barbarino, et al, considers the need for long-term value demonstration by identifying data gaps that must be addressed.

“Driven by our commitment to patients, Biogen remains focused on furthering Alzheimer’s disease research and treatment,” said Robin P. Thompson, PhD, Senior Director, Value and Access, Biogen. “We appreciate the opportunity to collaborate with ISPOR on this important project. The topics discussed in this supplement and the associated webinars are critical as stakeholders work together to improve care, research, and the development of new treatments, and, most importantly, ensure that all people and families affected by dementia receive the support they need.”

Visit to view the entire webinar series, which included the following presentations: (1) Valuing Future Alzheimer’s Disease Medicines: Extending the Paradigm; (2) Value Assessment in Alzheimer's Disease: A Focus on Equity; and (3) Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs.

Visit to learn more about its Alzheimer's disease investigational candidates and clinical trials.



ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram

Value & Outcomes Spotlight is ISPOR’s bimonthly news publication for the global HEOR community that provides feature articles on timely HEOR topics, methodological and health policy articles, as well as updates from ISPOR leadership and news from around the world.
Website  | Twitter (@isporjournals)

Related Stories

Global Experts Introduce Strategic Action Plan to Accelerate Patient Access to Next-Generation DNA Sequencing in Oncology

Sep 27, 2022

Value & Outcomes Spotlight, the health economics and outcomes research (HEOR) news magazine of ISPOR, announced the publication of a supplement, “A Plan of Action: Accelerating Patient Access to Next-Generation Sequencing in Oncology,” that details the challenges in improving patient access to next-generation DNA sequencing and proposes a plan of action to improve access.

Virtual ISPOR Europe 2020 Live Conference Concluded

Nov 23, 2020

ISPOR announced that its Virtual ISPOR Europe 2020 conference, “Improving Health: Establishing Incentives and Sharing Value,” is now available on demand through 31 December 2020. ISPOR Europe is the leading European conference for health economics and outcomes research.

New Editors-in-Chief Appointed for ISPOR’s Value & Outcomes Spotlight Magazine

Aug 4, 2020

ISPOR, the professional society for health economics and outcomes research (HEOR), announced today the appointment of 2 new Editors-in-Chief for its HEOR news magazine, Value & Outcomes Spotlight.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now